Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

Description

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.

Conditions

Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma, Stage A Prostate Cancer, Stage B Prostate Cancer, Stage C Prostate Cancer, Stage D Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.

Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-Induced Obese Frailty in Survivors of Advanced Prostate Cancer

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

Condition
Cancer Survivor
Intervention / Treatment

-

Contacts and Locations

Buffalo

Roswell Park Cancer Institute, Buffalo, New York, United States, 14263

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Biopsy-confirmed prostate adenocarcinoma of any stage/grade
  • * Prescribed or already receiving continuous ADT for \< 5 years
  • * Hemoglobin \> 11 g/dL
  • * Creatinine \< 1.5 x upper limit of normal (ULN), AST or ALT \<2 x ULN within 6 months prior to enrollment
  • * Liver function tests \< 2 x ULN
  • * Able to walk unassisted at least 100 meters (200 steps) or ECOG \<= 1
  • * No contraindications to any aspect of participation, including aerobic exercise
  • * Participant must be able to read, write, and understand the English language and be able to provide written consent
  • * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
  • * Known clinically significant severe chronic obstructive pulmonary disease (COPD), ischemic heart disease, congestive heart failure, and/or significant cardiac arrhythmias
  • * Limiting orthopedic, musculoskeletal or psychological conditions (clinician discretion)
  • * Overall medical frailty (clinician discretion)
  • * Any condition contraindicating additional blood collection beyond standard of care
  • * Unwilling or unable to follow protocol requirements
  • * Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Roswell Park Cancer Institute,

Gurkamal S Chatta, PRINCIPAL_INVESTIGATOR, Roswell Park Cancer Institute

Study Record Dates

2029-05-02